Autoplaque vs Rapid RV/LV
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if your primary need is a comprehensive, quantitative analysis of coronary plaque burden and luminal stenoses from CT angiography images. This tool is ideal for detailed risk stratification of patients with suspected or known coronary artery disease, aiding in long-term treatment planning and personalized management strategies.
View Autoplaque →Choose Rapid RV/LV if…
Choose Rapid RV/LV if you require a rapid, automated assessment of pulmonary embolism severity by measuring right and left ventricle ratios from CTPA scans. This tool is best suited for urgent clinical scenarios where quick triage and immediate decision-making are critical for patients presenting with suspected pulmonary embolism.
View Rapid RV/LV →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | Rapid RV/LV |
|---|---|---|
| Pricing | Unknown | Contact vendor for pricing information. |
| Deployment | Workstation-based post-processing application, runs on Windows or Mac OS. | On-premises (dedicated server or virtual machine) or hybrid (on-premises/cloud with secure link to cloud), connecting to hospital LAN/firewall. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Rapid RV/LVRapid RV/LV (Tool B) offers a more streamlined and integrated user experience, emphasizing rapid, automated results delivered to multiple platforms like PACS, email, and a mobile app, facilitating efficient workflow integration and team collaboration. Autoplaque (Tool A), while providing interactive clinician review and editing of segmentations, is workstation-based, suggesting a more localized and less integrated approach to workflow.
Clinical Value
AutoplaqueBoth tools are FDA-cleared and offer significant clinical value in their respective domains. Autoplaque (Tool A) provides detailed quantitative analysis of coronary plaques and luminal stenoses, aiding in heart attack risk prediction and treatment guidance, backed by over 100 peer-reviewed publications and multicenter trials. Rapid RV/LV (Tool B) offers rapid, automated assessment of pulmonary embolism severity, crucial for acute triage and treatment decisions, and reduces inter-rater variability. Autoplaque's depth in plaque characterization for long-term risk management and extensive validation gives it a slight edge.
Pricing & Value
Rapid RV/LVBoth tools have undisclosed pricing for the general public. However, RapidAI (Tool B) provides some insight into its pricing model, stating it's an enterprise-level software with custom quotes and a starting price for a single module. Autoplaque (Tool A) offers no public pricing information whatsoever, making Tool B slightly more transparent in this dimension.
Enterprise Readiness
Rapid RV/LVRapid RV/LV (Tool B) demonstrates superior enterprise readiness, explicitly stating HIPAA compliance, having a Business Associate Agreement (BAA), and holding multiple security certifications including GDPR, ISO 13485, ISO 27001, ISO 27701, and SOC2 Type 1. Its flexible deployment options (on-premises or hybrid) and integration capabilities with PACS and EHRs are designed for large-scale hospital system adoption. Autoplaque (Tool A), developed by an academic institution, is workstation-based and lacks explicit public statements on enterprise-level compliance or integration.
Innovation
Rapid RV/LVBoth tools are innovative in their applications of AI. Autoplaque (Tool A) offers detailed, quantitative characterization of coronary plaque, including 'dangerous plaque,' and has been validated against invasive methods, providing deep insights for preventative cardiology. Rapid RV/LV (Tool B) focuses on rapid, automated assessment for acute conditions, integrating with a broader platform for triage and notification, and aims to reduce cognitive burden while supporting both acute and longer-term management. RapidAI's broader platform approach and commitment to 'deep clinical AI' that goes beyond simple triage to characterize, quantify, visualize, and track changes over time, suggests a more expansive and integrated innovative vision.
Support & Docs
Rapid RV/LVRapid RV/LV (Tool B) is the clear winner, offering 24/7/365 dedicated customer support via email and phone with international contact numbers, along with a comprehensive library of resources including expert guides, videos, webinars, and case studies. Autoplaque (Tool A), developed by an academic institution, does not publicly detail specific customer support channels or extensive documentation beyond a user manual.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | Rapid RV/LV |
|---|---|---|
| Name | Autoplaque | Rapid RV/LV |
| Company | APQ Health (formerly Cedars-Sinai Medical Center: AIM) | RapidAI (formerly iSchemaView) |
| Tagline | AI-powered, automated quantitative analysis of atherosclerotic plaque from coronary CT angiography, providing physicians with a powerful tool for risk prediction and guiding treatment. | AI-powered rapid assessment of pulmonary embolism severity. |
| Primary Function | AI-powered quantitative analysis of atherosclerotic plaque and luminal stenoses from CT angiography images. | AI-powered rapid assessment of pulmonary embolism severity by automatically measuring right and left ventricle ratios from CTPA scans. |
| Specialties | Cardiology, Radiology | Cardiology, Pulmonology, Radiology |
| Data Export | DICOM image data | Not specified |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and Rapid RV/LV.